Newtown, PA, September 27, 2010 Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii. In vivo studies show that Ex-RAD, upon oral administration, produced a significant increase in survival versus placebo-treated groups in mice exposed to lethal whole body irradiation (WBI), for both prophylactic pre-treatment and mitigation post-treatment. Ex-RAD is the only known oral radioprotectant that has shown such activity in animal model systems.
Collectively, these presentations demonstrate the ability of Ex-RAD to provide radioprotective benefit by injection and oral delivery, an in-depth understanding of the kinetics and metabolism of Ex-RAD, and radioprotective benefit to human bone marrow, as well as the gastrointestinal and hematopoietic systems in mice.
Onconova, a biopharmaceutical company developing novel chemical entities to treat cancer and protect normal cells, is developing Ex-RAD, a novel radioprotectant with potential utility in bio-defense or bio-terrorism, which could prove useful as a prophylactic agent for first-responder protection from the harmful effects of radiation from nuclear accidents or weapons of mass destruction (WMD).
These presentations result from an on-going Onconova collaboration among investigators at a number of institutions: AFRRI, (The Armed Forces Radiobiology Research Institute) a part of the Uniformed Services University of the Health Sciences (USUHS); Georgetown University, Department of Biochemistry and Molecular & Cellular Biology; Long Island University, Arnold & Marie Schwartz College of Pharmacy; and the Department of Oncological Sciences, Mt. Sinai School of Medicine.
Summary of Oral Ex-RAD Findings
The results from a prophylactic radioprotection study in mice demonstrated that Ex-RAD dosed orally or by injection prior to lethal whole body irradiation (WBI) produced significant enhancement in survival for both Ex-RAD treated groups versus placebo.
Results from the radiomitigation experiment (where the drug is administered after exposure to lethal radiation), using both injection and oral methods of delivery demonstrated that Ex-RAD treated animals had comparably high rates of survival in both groups.
Hence, oral Ex-RAD was found to be effective in both prophylactic pre-treatment and mitigation post-treatment settings.
"Years of collaborative work are resulting in great progress with Ex-RAD in the laboratory and the clinic and Ex-RAD is the focus of several posters and a key presentation within the RSS scientific and educational track," said Manoj Maniar, PhD, Senior Vice President for Product Development of Onconova. "We are very excited to see the acceleration and new developments within radioprotection, specifically in oral prophylaxis and treatment. Ex-RAD holds a unique position among developing products with the potential to benefit people exposed to whole body radiation."
Onconova oral presentation and poster sessions on Ex-RAD at the Radiation Research Society meeting:
WEDNESDAY, SEPTEMBER 29, 2010
Poster Sessions Radiation Protection Protection / Mitigators / Treatment
SUNDAY, SEPTEMBER 26, 2:00 pm-2:45 pm, 2010, Haleakala Foyer
Poster Sessions Experimental Therapeutics and Translational Research
WEDNESDAY, SEPTEMBER 29, 5:30 PM-6:15 PM, 2010 Haleakala Foyer
|Contact: Katrhyn Morris|
PR on Call